Age-Related Macular Degeneration (AMD) is the leading cause of irreversible blindness in the developed world, robbing older individuals of their sight and autonomy. New treatments have transformed lives for patients with “wet” AMD, but benefit just 15% of all patients with late-stage disease. The remaining 85% of patients with AMD have the “dry” form. In fact, early in disease, all patients start with dry AMD.
There is currently NO TREATMENT for dry AMD
An estimated 1 in 11 individuals has a diagnosis of AMD by 65 years of age. This rises to 1 in 4 by age 75. AMD accounts for over half of all referrals to the CNIB and is referred to as a “time bomb of vision loss” by the American Academy of Ophthalmology. With an aging population, the need for treatment has never been greater.
We are dedicated to saving sight of patients with Age Related Macular Degeneration
Turning science into medicine is not a straight arrow that points one way. While great science drives great medicine, extensive knowledge from the clinic must strategically guide early research.
Driven by a passion for patient care, we have engineered our scientific program and developed a translational platform that extends from disease model, to biomarker, to compounds that have pre-clinical efficacy with known clinical safety.